2010
DOI: 10.1016/j.neuroscience.2010.05.019
|View full text |Cite
|
Sign up to set email alerts
|

Effects of a new potent analog of tocainide on hNav1.7 sodium channels and in vivo neuropathic pain models

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
25
0

Year Published

2012
2012
2022
2022

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 38 publications
(25 citation statements)
references
References 40 publications
0
25
0
Order By: Relevance
“…Drugs that target Na v 1.7 activity could, thus, prove useful in conjunction with existing therapies. Na v -specific blockers are already in clinical use as local anaesthetics and, more recently, Na v 1.7-specific inhibitors are being developed for the treatment of pain (Bregman et al, 2011;Chowdhury et al, 2011;Clare, 2010;Ghelardini et al, 2010). Given its functional significance and marked upregulation in tumour tissue, we suggest that Na v 1.7 represents an important new target for therapeutic intervention and/or as a diagnostic and/or prognostic marker in NSCLC.…”
Section: -Test) Continuous Lines Indicatementioning
confidence: 96%
“…Drugs that target Na v 1.7 activity could, thus, prove useful in conjunction with existing therapies. Na v -specific blockers are already in clinical use as local anaesthetics and, more recently, Na v 1.7-specific inhibitors are being developed for the treatment of pain (Bregman et al, 2011;Chowdhury et al, 2011;Clare, 2010;Ghelardini et al, 2010). Given its functional significance and marked upregulation in tumour tissue, we suggest that Na v 1.7 represents an important new target for therapeutic intervention and/or as a diagnostic and/or prognostic marker in NSCLC.…”
Section: -Test) Continuous Lines Indicatementioning
confidence: 96%
“…8 Multiple lines of evidence show that they have been implicated in the development of inflammatory pain 9,10 and neuropathic pain. [11][12][13] Furthermore, dysregulation of VGSCs in injured sensory neurons is also involved in the development of painful peripheral neuropathy in a rat model of diabetes. [14][15][16][17] However, roles for Na V 1.7 and Na V 1.8 in colonic hypersensitivity in streptozotocin (STZ)-induced diabetic rats remain unknown.…”
Section: Introductionmentioning
confidence: 99%
“…Making the alkyl chain even longer seemed to be unnecessary due to local irritative effect and poor aqueous solubility, previously reported for the similar structures with longer N-alkyl chain in the pyrrolidine ring [22]. The cyclohexyl substituted derivatives 4n and 4o demonstrated practically the same level and duration of anaesthesia as their corresponding n-butyl analogues 4c, e. Interestingly, despite recent reports [25][26][27] on high in vitro sodium channel blocking potential of 2,6-xylidine analogue of 4m -NeP1 ( Fig. 1), introduction of a N-benzyl moiety into the pyrrolidine ring of ortho-toluidine derivative appeared to abolish anaesthetic activity.…”
Section: Surface Local Anaesthetic Activitymentioning
confidence: 75%